Adjuvant chemo-endocrine therapy for androgen-dependent mammary tumor in mice

Breast Cancer Res Treat. 1981;1(1):69-75. doi: 10.1007/BF01807894.

Abstract

About 500 male DS mice grafted with androgen-dependent Shionogi carcinoma 115 (SC115) were used. When the tumor diameter reached about 20 mm (approximately 25 days after transplantation), excision of the tumor and/or castration were carried out. The injection of cyclophosphamide (80 mg/kg body weight X 3 at 7-day intervals) was started from the day after excision. In mice with excised tumor, adjuvant chemo-endocrine therapy was the most effective treatment examined; cumulative 120-day mortalities after transplantation of tumors in non-treated, adjuvant endocrine therapy, adjuvant chemotherapy and adjuvant chemo-endocrine therapy groups were 91%, 29%, 21% and 0%, respectively. Castration induced development of clusters of androgen-independent cancer cells in androgen-dependent SC115 tumor. In mice without tumor excision, the chemo-endocrine therapy was again the most effective treatment, though 86% of mice died by the 120th day after tumor transplantation. These findings suggest the usefulness of adjuvant chemo-endocrine therapy for achieving complete remission in hormone-dependent tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androgens / metabolism
  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Castration
  • Cyclophosphamide / therapeutic use*
  • Male
  • Mammary Neoplasms, Experimental / drug therapy*
  • Mammary Neoplasms, Experimental / surgery
  • Mice
  • Neoplasm Transplantation
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Neoplasms, Hormone-Dependent / surgery

Substances

  • Androgens
  • Antineoplastic Agents
  • Cyclophosphamide